Europe Breast Cancer Screening Market Forecast Report And Company Analysis 2024-2032 Featuring Astrazeneca, Novartis, Sanofi, Pfizer, Bayer, And Glaxosmithkline

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The "Europe Breast Cancer Screening Market Forecast Report by Europe Breast Cancer Screening Market, Countries, and Company Analysis, 2024-2032" report has been added to ResearchAndMarkets.com's offering.
The Europe Breast Cancer screening Market was valued at US$ 1.12 Billion in 2023 and will grow to US$ 11.85 Billion by 2032, with a CAGR of 7.85% from 2024 to 2032. The main factors propelling the European breast cancer market are heightened government support for the integration of new medicines, a greater number of treatments introduced by the top companies in the industry, and enhanced research and development.

Important drivers propelling the market's growth include the rising prevalence of breast cancer, the existence of major competitors in the European breast cancer screening market, and strong research and development. In the UK, over 58,000 women and 380 men receive a breast cancer diagnosis annually. Every year, over 47,000 individuals in England are given a breast cancer diagnosis.

Approximately 4,800 individuals in Scotland receive a breast cancer diagnosis annually. Every year, over 2,900 people in Wales receive a breast cancer diagnosis. With a frequency of 565,500 cases in 2019, breast cancer is the most prevalent cancer among women in the European region, and 1 in 8 of these women will have the disease before the age of 85, according to EUROPA DONNA, the European Coalition Against Breast Cancer. As a result, breast cancer often strikes women in their prime, which is expected to fuel market expansion in the years ahead.
The primary causes of the rising incidence of breast cancer are bad lifestyle choices like smoking, eating poorly, getting sick, and having a strong family history. This raises the need for gold-standard mammograms, and other diagnostic imaging tests, blood, and laboratory testing are becoming more and more common. According to the Globocan study, 32,900 new cases of breast cancer were found in Spain in 2019, and 6,500 deaths from the disease were recorded.

The demand for routine screening and technological improvement is growing as a result of the rise in breast cancer cases in Spain. To improve the prognosis for breast cancer patients with an early diagnosis, a number of local governments and other healthcare organizations throughout Europe are holding free breast screening events and providing education.
The Market expansion is driven by rising breast cancer incidence
Because breast cancer is becoming more commonplace globally and more individuals are anticipated to require precise and efficient treatment alternatives, the European breast cancer market's compound annual growth rate (CAGR) is increasing. Since breast cancer is one of the most prevalent malignancies worldwide, more people are anticipated to receive diagnoses in the future as a result of improved diagnostics. The development of new technologies with state-of-the-art features for treatments and enhanced treatment efficacy is a key factor driving the market value growth.
Increased pharmaceutical developments, new product releases by significant industry players, better patient treatment outcomes, higher pharmacological efficacy and effectiveness, and recently developed therapeutics for the condition all contribute to the growth of the breast cancer market.
In addition, there has been a rise in the incidence of breast cancer among individuals due to factors such as decreased exercise, obesity, increased alcohol consumption, menopause, hormone issues, and family histories of cancer, as well as the government's increased support for the introduction of novel treatments and medications into the healthcare sector. Boost government advantages by creating more regulations, such reimbursement guidelines, to enable the general public to benefit from pricey medical procedures. As a result of the introduction of new laws and increased cost-effectiveness, the breast cancer market is driven by revenue growth.
The market is expanding in part because of the increasing number of clinical trials being conducted for the creation and assessment of screening tests.
Another factor fueling the market's expansion is the increase in clinical trials for the creation and assessment of screening tests. For example, a clinical trial supported by the University Medical Center, Utrecht, Netherlands, is anticipated to be finished by April 2023, according to In this study, women aged 50-75 who exhibit higher than 75% mammographic density will have their biennial screening with mammography plus MRI compared to mammography alone, to see which is more cost-effective. Growing clinical trials are anticipated to provide market participants with a chance to develop cutting-edge screening tests, which will further propel the market's expansion.
Key Attributes:

Report Attribute	Details
No. of Pages	240
Forecast Period	2023 - 2032
Estimated Market Value (USD) in 2023	$1.03 Billion
Forecasted Market Value (USD) by 2032	$2.21 Billion
Compound Annual Growth Rate	8.8%
Regions Covered	Europe

Company Analysis:

• AstraZeneca
• Novartis
• Sanofi
• Pfizer
• Bayer AG
• GlaxoSmithKline plc

Key Topics Covered:
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Europe Breast Cancer Screening Population Analysis
5.1 Europe Breast Cancer Mammography Screening Population
5.2 Europe Breast Cancer MRI & Ultrasound Screening Population
6. Europe Breast Cancer Screening Market Analysis
6.1 Europe Breast Cancer Screening Market
6.1.1 Mammography Screening Market
6.1.2 MRI Screening Market
6.1.3 Ultrasound Screening Market
7. Europe Breast Cancer Screening Population Share Analysis
7.1 Mammography Screening Population Share
7.2 MRI & Ultrasound Screening Population Share
8. Europe Breast Cancer Screening Market Share Analysis
8.1 Worldwide Breast Cancer Screening Market Share
8.2 Mammography Screening Market Share
8.3 MRI Screening Market Share
8.4 Ultrasound Screening Market Share
9. United Kingdom
9.1 United Kingdom Breast Cancer Mammography Screening Population
9.2 United Kingdom Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
9.3 United Kingdom Breast Cancer Screening Market
9.3.1 Mammography Screening Market
9.3.2 Magnetic Resonance Imaging (MRI) Screening Market
9.3.3 Ultrasound Screening Market
10. France
10.1 France Breast Cancer Mammography Screening Population
10.2 France Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
10.3 France Breast Cancer Screening Market
10.3.1 Mammography Screening Market
10.3.2 Magnetic Resonance Imaging (MRI) Screening Market
10.3.3 Ultrasound Screening Market
11. Germany
11.1 Germany Breast Cancer Mammography Screening Population
11.2 Germany Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
11.3 Germany Breast Cancer Screening Market
11.3.1 Mammography Screening Market
11.3.2 Magnetic Resonance Imaging (MRI) Screening Market
11.3.3 Ultrasound Screening Market
12. Italy
12.1 Italy Breast Cancer Mammography Screening Population
12.2 Italy Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
12.3 Italy Breast Cancer Screening Market
12.3.1 Mammography Screening Market
12.3.2 Magnetic Resonance Imaging (MRI) Screening Market
12.3.3 Ultrasound Screening Market
13. Spain
13.1 Spain Breast Cancer Mammography Screening Population
13.2 Spain Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
13.3 Spain Breast Cancer Screening Market
13.3.1 Mammography Screening Market
13.3.2 Magnetic Resonance Imaging (MRI) Screening Market
13.3.3 Ultrasound Screening Market & Forecast
14. Switzerland
14.1 Switzerland Breast Cancer Mammography Screening Population
14.2 Switzerland Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
14.3 Switzerland Breast Cancer Screening Market
14.3.1 Mammography Screening Market
14.3.2 Magnetic Resonance Imaging (MRI) Screening Market
14.3.3 Ultrasound Screening Market
15. Norway
15.1 Norway Breast Cancer Mammography Screening Population
15.2 Norway Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
15.3 Norway Breast Cancer Screening Market
15.3.1 Mammography Screening Market
15.3.2 Magnetic Resonance Imaging (MRI) Screening Market
15.3.3 Ultrasound Screening Market
16. Netherlands
16.1 Netherlands Breast Cancer Mammography Screening Population
16.2 Netherlands Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
16.3 Netherlands Breast Cancer Screening Market
16.3.1 Mammography Screening Market
16.3.2 Magnetic Resonance Imaging (MRI) Screening Market
16.3.3 Ultrasound Screening Market
17. Porter's Five Forces
17.1 Bargaining Power of Buyer
17.2 Bargaining Power of Supplier
17.3 Threat of New Entrants
17.4 Rivalry among Existing Competitors
17.5 Threat of Substitute Products
18. SWOT Analysis
18.1 Strengths
18.2 Weaknesses
18.3 Opportunities
18.4 Threats

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• European Breast Cancer Screening Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN04092024004107003653ID1108636379